Factor VIII Gene Integration in Albumin for Stable Liver Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Genetic disorders caused by deficiencies in liver-produced factors, such as hemophilia A and B, result from mutations in genes encoding coagulation factors like Factor VIII, leading to inadequate blood clotting.

Innovation Solution

A gene therapy approach using engineered nucleases and donor templates to integrate functional Factor VIII genes into the liver's albumin gene, leveraging endonucleases, guide polynucleotides, and donor templates to achieve continuous liver enzyme expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If gene therapy approaches integrate liver genes encoding functional liver enzymes into the genome in vivo, then continuous expression of functional enzymes is achieved, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improvecontinuous expression of functional enzymesVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The gene therapy system is divided into three distinct components: (1) an endonuclease (such as CRISPR-Cas9) that creates targeted DNA breaks, (2) a guide polynucleotide that directs the endonuclease to the specific genomic location, and (3) a donor template that provides the functional gene sequence for integration. This segmentation allows each component to be optimized independently and delivered through established vectors, reducing overall protocol complexity while ensuring reliable continuous expression of functional liver enzymes.

Inventive Principle:

Principle #1Segmentation

2Stability of the object's composition

If engineered nucleases and donor templates are used to integrate functional Factor VIII genes into the liver's albumin gene, then stable liver enzyme supplementation is achieved, but the manufacturing complexity increases

Engineering Contradiction:

Improvestable liver enzyme supplementationVSAvoidmanufacturing complexity

Core Design Contradiction:

Stability of the object's compositionVSEase of manufacture

Solution Approach 1:

The endonuclease system is designed to be universally applicable to multiple liver enzyme genes beyond just Factor VIII. The same core components (endonuclease, guide polynucleotide structure, donor template design) can target different genomic locations and different enzyme genes by simply changing the guide sequence and donor template content. This universality simplifies manufacturing by allowing a single production platform to serve multiple therapeutic indications, reducing overall manufacturing complexity while maintaining stable enzyme supplementation.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Manufacturing precision

If the endonuclease creates a double-stranded break at the target site, then integration of the donor template is enabled, but the risk of off-target effects increases

Engineering Contradiction:

Improveintegration precisionVSAvoidoff-target effects

Core Design Contradiction:

Manufacturing precisionVSObject-affected harmful factors

Solution Approach 1:

A guide polynucleotide serves as an intermediary between the endonuclease and the target DNA sequence. This guide molecule provides high-specificity binding through complementary base pairing, directing the endonuclease precisely to the intended genomic location (such as the albumin gene locus) while preventing off-target binding. The guide polynucleotide acts as a molecular address label that ensures the double-stranded break occurs only at the correct site, enabling precise donor template integration while minimizing harmful off-target effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

4Productivity

If the donor template includes nucleus-targeting sequences, then nuclear delivery efficiency is improved, but the device complexity increases

Engineering Contradiction:

Improvenuclear delivery efficiencyVSAvoiddonor template structure

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

Nucleus-targeting sequences (such as nuclear localization signals or transcription factor binding sites) are pre-included in the donor template design before delivery. This preliminary action ensures that once the donor template enters the cell, it is actively directed to the nucleus where genomic integration occurs, rather than remaining in the cytoplasm. By building this targeting capability into the template structure in advance, nuclear delivery efficiency is significantly improved without requiring complex external delivery systems or multiple-step protocols.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables stable and efficient supplementation of liver enzymes, specifically Factor VIII, addressing the genetic deficiencies and improving blood clotting capabilities.

Implementation Method 1

an endonuclease comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 54 or SEQ ID NO: 96

Methodology Applied

Scientific EffectEndonuclease cleavage: Enzyme

Implementation Method 2

an engineered guide polynucleotide configured to form a complex with the endonuclease and to hybridize to a target nucleic acid sequence within an albumin gene

Methodology Applied

Scientific EffectHybridization: